RENAL CELL CARCINOMA

This study tests whether adding an experimental mRNA vaccine (V940) to standard immunotherapy (pembrolizumab) can better prevent kidney cancer from returning after surgery. About 272 people with high-risk kidney cancer will receive either the vaccine plus immunotherapy or a place…

This study tests a personalized treatment plan for people with advanced kidney cancer. It combines two drugs: an immunotherapy (pembrolizumab) and a targeted therapy (axitinib). The dose of each drug is adjusted based on how the patient's tumor responds. The goal is to see if thi…

This early-phase trial tests the safety and best dose of a combination of two or three drugs (cabozantinib, nivolumab, and possibly ipilimumab) in people with advanced genitourinary cancers that have spread. About 152 adults with these cancers will participate. The goal is to fin…

This phase 3 trial tested whether combining lenvatinib with either everolimus or pembrolizumab works better than the standard drug sunitinib alone for people with advanced kidney cancer. Over 1,000 participants were randomly assigned to one of three treatment groups. The study me…

This early-phase study tests whether a new immune cell therapy called CIML NK cells, combined with a low dose of IL-2, is safe and feasible for people with advanced kidney or bladder cancers. The therapy uses a patient's own immune cells that are trained in a lab to better recogn…

This early-phase study tests an investigational cell therapy called P-MUC1C-ALLO1 in adults with advanced solid tumors (e.g., breast, ovarian, lung, pancreatic cancers) that have not responded to standard treatments. The main goals are to find a safe dose and check for early sign…

This study tests two new drug combinations for people with advanced kidney cancer that hasn't been treated before. About 199 participants will receive either a standard treatment or one of two experimental combos to see if they are safer and work better. The goal is to control th…

This study tests whether giving immunotherapy before surgery can shrink tumors in people with a type of kidney cancer that is at high risk of coming back. About 69 adults with clear cell renal cell carcinoma will receive one of three drug combinations (nivolumab alone, nivolumab …

This early-phase study tested a vaccine (p53MVA) plus the drug pembrolizumab in 11 adults with advanced solid tumors that had stopped responding to other treatments. The goal was to see if the combination is safe and can boost the immune system to attack cancer cells. Participant…

This study tests a new drug combination (belzutifan plus palbociclib) against belzutifan alone in people with advanced kidney cancer that has worsened after at least two prior treatments. The goal is to see if the combo is safe and can better control the disease. About 60 adults …

This study tests whether combining two immunotherapy drugs (BGB-A445 and tislelizumab) can shrink tumors in people with advanced bladder, kidney, or skin cancer that has spread. About 113 participants who have already tried at least one prior treatment will receive the drug combo…

This study tests whether combining two immunotherapy drugs (nivolumab and ipilimumab) works better than one drug alone for people with advanced kidney cancer that hasn't been treated before. About 437 participants with intermediate- or poor-risk disease will receive either the co…

This study tests an experimental drug (ARRY-614) combined with standard immunotherapies (nivolumab or nivolumab plus ipilimumab) in people with advanced solid tumors like lung, kidney, skin, and head/neck cancers. The first part finds the safest dose, and the second part checks i…

This study tests a drug called cabozantinib in children and young adults (up to age 30) with rare cancers like sarcomas, Wilms tumor, and others that have come back or not responded to standard therapy. The drug works by blocking enzymes that help tumors grow and form blood vesse…

This early-phase study tests a new drug called AB248, alone or with another drug (pembrolizumab), in adults with advanced solid tumors like lung cancer, melanoma, head and neck cancer, and kidney cancer. The main goals are to check safety and find the right dose. About 552 people…

This study tests whether adding ciforadenant to two immunotherapy drugs (ipilimumab and nivolumab) can better control advanced renal cell carcinoma. It involves 50 adults with stage IV kidney cancer who have not had prior treatment. The goal is to see how many patients respond to…

This study is for people with advanced solid tumors (like lung, bladder, or skin cancer) whose disease has progressed after standard immunotherapy. It tests a new drug combination designed to boost the immune system to fight cancer. About 40 participants will receive the experime…

This study tests an experimental drug called INBRX-106, given alone or with the immunotherapy pembrolizumab (Keytruda), in people with advanced solid tumors (like lung, head and neck, melanoma, stomach, kidney, or bladder cancer) that have stopped responding to standard treatment…

This study tests a drug called 177Lu-PSMA-617, which delivers radiation directly to cancer cells, in people with advanced clear cell kidney cancer that has spread. The goal is to see if it can shrink tumors and how safe it is. The trial involves 24 participants and is currently a…

This study tests whether adding the targeted drug cabozantinib to a standard immunotherapy combo (nivolumab and ipilimumab) helps people with advanced kidney cancer live longer without their cancer growing. About 855 adults with intermediate- or high-risk kidney cancer that has s…

This study tests whether a combination of three drugs (cabozantinib, nivolumab, and ipilimumab) can safely slow the growth of advanced or spreading kidney cancer in people with rare types of the disease. About 60 adults with non-clear cell kidney cancer that cannot be surgically …

This study tests an experimental drug called HFB200603, alone or with another immunotherapy (tislelizumab), in adults with advanced solid tumors like kidney, lung, skin, stomach, or colorectal cancer. The goal is to find a safe dose and see how well the body tolerates it. About 8…

This study looks at how well surgery to remove kidney cancer tumors (including those that have spread) works for controlling the disease. About 86 people with kidney cancer will have the surgery and then be followed to see if the cancer comes back. The goal is to learn if this ap…

This study tests a new device called GPX® Embolic Device for blocking blood flow to tumors and other areas in the body. About 114 adults who need this procedure will take part. The goal is to see if the device is safe and works well at reaching and blocking small blood vessels.

This study tests giving a short course of high-precision radiation (SABR) to the tumor clot in the main vein before surgery to remove it. The goal is to see if this approach is safe and helps prevent the cancer from coming back within a year. About 25 adults with newly diagnosed …

This early-phase study tests whether adding an experimental drug (APX005M) to two standard immunotherapies is safe and tolerable for people with advanced melanoma or kidney cancer. About 26 adults who have not had prior immune therapy for their advanced disease will receive the c…

This study tests a freezing treatment (cryotherapy) for kidney cancer tumors up to 5 cm. Doctors use the ProSense™ system to freeze and destroy the tumor, checking if the ice ball covers the whole tumor plus a small safety margin. The study follows 120 patients for 5 years to see…

This study tests a new two-drug combination (cadonilimab plus axitinib) as a first treatment for people with advanced or spread kidney cancer of rare types. About 37 adults will take the drugs until their disease gets worse or side effects become too severe. The goal is to see if…

This study tests whether giving the drug sunitinib before surgery can help control metastatic kidney cancer. About 50 adults with clear cell renal cell carcinoma who are eligible for kidney removal surgery are participating. Researchers track how long the cancer stays under contr…

This study tests whether the drug cabozantinib can shrink kidney tumors before surgery in people with locally advanced clear cell renal cell carcinoma. About 22 participants will receive cabozantinib before their operation. The goal is to see if the drug reduces tumor size and he…

This study compares two FDA-approved drugs, cabozantinib and sunitinib, in people with a rare type of advanced kidney cancer called variant histology renal cell carcinoma. The goal is to see which drug is safer and more effective at controlling the cancer. About 32 participants w…

This study tests a drug called entrectinib in people with advanced solid tumors that have certain gene changes (NTRK, ROS1, or ALK). The drug aims to shrink or control the cancer by blocking these faulty genes. About 534 adults with various cancers, including lung, breast, and br…

This early-phase study tests whether giving kidney cancer patients a fecal microbiota transplant (FMT) before and during immunotherapy can prevent severe side effects like colitis. About 20 adults with advanced kidney cancer will receive FMT alongside the drugs ipilimumab and niv…

This early-phase study tests a new drug, AI-061, which combines two immunotherapy agents (anti-PD-1 and anti-CTLA-4) into one treatment for people with advanced solid tumors that have stopped responding to standard therapies. The main goal is to find the safest dose and check for…

This study tests a combination of two drugs, nivolumab and axitinib, in people with advanced kidney cancer. The goal is to find the safest dose and see how well the drugs shrink tumors. About 98 participants, both previously treated and untreated, will take part. The study is in …

This study tests an experimental drug called HFB200301, alone or with another drug (tislelizumab), in adults with advanced solid tumors like stomach, kidney, or lung cancer. The main goal is to find safe doses and check for side effects. About 72 people will take part, and the st…

This early-phase trial tests a combination of two drugs, naptumomab estafenatox and durvalumab, in adults with advanced solid tumors that have not responded to standard treatments. The main goal is to find a safe dose and check for side effects. About 120 people with various canc…

This study aimed to see if a material called PuraBond could safely and effectively stop bleeding during robotic partial nephrectomy for kidney cancer. It was designed for adults undergoing this surgery. However, the study was withdrawn before any participants were enrolled, so no…

This early-phase study tests a new drug called belzutifan, alone or combined with lenvatinib and pembrolizumab, in about 45 Chinese adults with advanced kidney cancer that cannot be removed by surgery. The main goals are to check safety and how the body processes the drugs. This …

This study looks at whether people with certain cancers prefer getting the drug pembrolizumab as a shot under the skin instead of through an IV. About 147 participants will try both methods and report which they like better. The goal is to see if the shot is a more convenient opt…

This study looks at two ways to give radiation to people with cancer that has spread to the brain. All participants are also receiving immunotherapy. The standard approach gives a single high dose of radiation, while the experimental approach gives a lower dose over a few days. T…

This study looks at the bacteria and fungi living in the urinary tract of people with calcium kidney stones or kidney cancer, compared to healthy volunteers. Researchers will collect urine, stone fragments, and tissue samples to map the microbial community. The goal is to better …

This study tests whether a special type of CT scan (DCE-CT) can show early on if targeted therapy drugs for advanced kidney cancer are working. About 120 adults with metastatic renal cell carcinoma will get these scans before and shortly after starting treatment. The goal is to s…

This study looks back at medical records of 72 American Indian adults with cancers like lung, melanoma, and kidney who received immunotherapy. Researchers compare their outcomes, such as cancer progression and side effects, to those of White patients. The goal is to spot any diff…

This study looks at whether having patients report their side effects through a weekly survey can help doctors better manage symptoms from oral kidney cancer medications. About 42 adults with advanced kidney cancer will take a short survey each week about symptoms like nausea and…

This study tests a special needle with a tiny tracking device inside, like a mini GPS, to help doctors find hard-to-see tumors during biopsies or ablation procedures. About 3,900 adults with certain cancers or growths will take part. The goal is to see if this tool can place the …

This study explores whether a special PET/CT scan can help doctors see how kidney cancer responds to immunotherapy. About 46 people with advanced kidney cancer will get the scan before surgery or treatment. The goal is to learn if the scan can predict treatment outcomes, not to p…

This study is a registry that gathers medical information, tumor samples, and scans from people of any age with TFE renal cell carcinoma, a rare kidney cancer. The goal is to help researchers better understand the disease and develop more effective treatments. No experimental the…

This study tests a small implantable device that releases tiny amounts of 19 different cancer drugs directly into kidney tumors. The device is placed and removed during planned surgery. The goal is to see if this approach is safe and can help doctors learn which drugs work best f…